trial

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

NCTId NCT00435370
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 179 (actual)
Sponsored by Baylor College of Medicine
Primary completion 2011-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
179 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-11
Primary completion
2011-02
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
TropisetronRisperidone

Sponsors

Baylor College of MedicineLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Thomas Kosten, MDPrincipal Investigator

Sites

2 total
Houston, United StatesBeijing, China

Linked catalysts

1
Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Percep — primary completion2011-02

Facts & assertions

4 sourced
Enrollment
179
Phase
PHASE3
Primary Completion Date
2011-02
Status
COMPLETED
relationships
The graph out of here
drug
Tropisetron
drug
Risperidone
drug
lead_sponsor
Baylor College of Medicine
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Smoking Cessation
indication
Schizophrenia
indication
Smoking Cessation
indication
investigator
Thomas Kosten, MD
person